TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
55.83
+2.20 (4.10%)
At close: Jun 26, 2026, 4:00 PM EDT
55.80
-0.03 (-0.05%)
After-hours: Jun 26, 2026, 7:59 PM EDT
TG Therapeutics Employees
TG Therapeutics had 399 employees as of December 31, 2025. The number of employees increased by 61 or 18.05% compared to the previous year.
Employees
399
Change (1Y)
61
Growth (1Y)
18.05%
Revenue / Employee
$1,755,261
Profits / Employee
$1,157,634
Market Cap
7.91B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| ImmunityBio | 691 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| Mirum Pharmaceuticals | 418 |
| Rhythm Pharmaceuticals | 414 |
| Immunovant | 315 |
| Kymera Therapeutics | 253 |
TGTX News
- 5 days ago - TG Therapeutics price target raised to $83 from $57 at Jefferies - TheFly
- 17 days ago - TG Therapeutics Transcript: AGM 2026 - Transcripts
- 18 days ago - TG Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 19 days ago - TG Therapeutics announces Briumvi data, initiates clinical trial - TheFly
- 19 days ago - TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial - GlobeNewsWire
- 25 days ago - TG Therapeutics rises 10.6% - TheFly
- 25 days ago - TG Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 25 days ago - TG Therapeutics announces results from Briumvi trial - TheFly